AEterna Zentaris Company Profile (NASDAQ:AEZS)

About AEterna Zentaris (NASDAQ:AEZS)

AEterna Zentaris logoAeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AEZS
  • CUSIP: N/A
  • Web: www.aezsinc.com
Capitalization:
  • Market Cap: $32.97 million
  • Outstanding Shares: 14,333,000
Average Prices:
  • 50 Day Moving Avg: $1.19
  • 200 Day Moving Avg: $2.14
  • 52 Week Range: $0.78 - $5.59
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.26
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $930,000.00
  • Price / Sales: 35.45
  • Book Value: $0.39 per share
  • Price / Book: 5.90
Profitability:
  • EBIDTA: ($27,830,000.00)
  • Net Margins: -2,732.69%
  • Return on Equity: -425.52%
  • Return on Assets: -79.10%
Debt:
  • Current Ratio: 5.61%
  • Quick Ratio: 5.61%
Misc:
  • Average Volume: 2.17 million shs.
  • Beta: 1.1
  • Short Ratio: 0.26
 
Frequently Asked Questions for AEterna Zentaris (NASDAQ:AEZS)

What is AEterna Zentaris' stock symbol?

AEterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS."

How were AEterna Zentaris' earnings last quarter?

AEterna Zentaris Inc. (NASDAQ:AEZS) announced its quarterly earnings data on Monday, May, 8th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.33) by $0.02. The firm earned $0.26 million during the quarter, compared to analysts' expectations of $0.85 million. AEterna Zentaris had a negative net margin of 2,732.69% and a negative return on equity of 425.52%. The company's revenue for the quarter was up 8.3% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.37) earnings per share. View AEterna Zentaris' Earnings History.

Where is AEterna Zentaris' stock going? Where will AEterna Zentaris' stock price be in 2017?

3 analysts have issued twelve-month price targets for AEterna Zentaris' shares. Their predictions range from $3.00 to $6.00. On average, they anticipate AEterna Zentaris' stock price to reach $4.33 in the next year. View Analyst Ratings for AEterna Zentaris.

What are analysts saying about AEterna Zentaris stock?

Here are some recent quotes from research analysts about AEterna Zentaris stock:

  • 1. According to Zacks Investment Research, "AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. " (7/11/2017)
  • 2. Maxim Group analysts commented, "Summary Aeterna Zentaris announced its plan to file a new drug application (NDA) for Macrilen (macimorelin) for adults growth hormone deficiency (AGHD) in 3Q17, following its meeting with the FDA on March 29, 2017." (3/30/2017)

Who are some of AEterna Zentaris' key competitors?

Who are AEterna Zentaris' key executives?

AEterna Zentaris' management team includes the folowing people:

  • David A. Dodd, Chairman of the Board, President, Chief Executive Officer
  • Dennis Turpin CA, Chief Financial Officer, Senior Vice President
  • Philip Allen Theodore, Senior Vice President, Chief Administrative Officer, General Counsel
  • Richard Sachse M.D. Ph.D., Senior Vice President, Chief Scientific Officer, Chief Medical Officer
  • Jude Dinges, Chief Commercial Officer, Senior Vice President
  • Genevieve Lemaire, Chief Accounting Officer, Vice President - Finance
  • Michael Teifel, Vice President - Non-Clinical Sciences
  • Juergen H. L. Ernst, Lead Independent Director
  • Michael A. Cardiff, Director
  • Kenneth E. Newport CPA, Director

How do I buy AEterna Zentaris stock?

Shares of AEterna Zentaris can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AEterna Zentaris' stock price today?

One share of AEterna Zentaris stock can currently be purchased for approximately $2.30.


MarketBeat Community Rating for AEterna Zentaris (NASDAQ AEZS)
Community Ranking:  3.4 out of 5 (  )
Outperform Votes:  180 (Vote Outperform)
Underperform Votes:  88 (Vote Underperform)
Total Votes:  268
MarketBeat's community ratings are surveys of what our community members think about AEterna Zentaris and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for AEterna Zentaris (NASDAQ:AEZS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.33 (88.41% upside)

Analysts' Ratings History for AEterna Zentaris (NASDAQ:AEZS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/19/2017Maxim GroupBoost Price TargetBuy -> Buy$2.00 -> $4.00HighView Rating Details
7/5/2017HC WainwrightSet Price TargetBuy$3.00HighView Rating Details
1/8/2017Canaccord GenuitySet Price TargetBuy$7.50 -> $6.00N/AView Rating Details
(Data available from 7/24/2015 forward)

Earnings

Earnings History for AEterna Zentaris (NASDAQ:AEZS)
Earnings by Quarter for AEterna Zentaris (NASDAQ:AEZS)
Earnings History by Quarter for AEterna Zentaris (NASDAQ AEZS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/20173/31/2017($0.33)($0.31)$0.85 million$0.26 millionViewListenView Earnings Details
3/15/201712/31/2016($0.73)($0.71)$0.40 million$0.30 millionViewN/AView Earnings Details
11/8/2016Q316($0.74)($0.61)$0.22 million$0.27 millionViewListenView Earnings Details
5/9/2016Q216($0.82)($0.71)$0.50 million$0.24 millionViewN/AView Earnings Details
3/29/2016Q415($1.30)($1.46)$0.25 million$0.10 millionViewN/AView Earnings Details
11/5/2015Q315($0.06)($0.07)$0.20 million$0.17 millionViewN/AView Earnings Details
8/13/2015Q215($0.08)($0.14)$0.55 million$0.20 millionViewListenView Earnings Details
5/7/2015Q1 2015($0.10)($0.13)$0.07 millionViewN/AView Earnings Details
3/17/2015Q414($0.16)$0.06$0.01 millionViewN/AView Earnings Details
3/20/2014Q413($0.04)($0.22)$12.41 millionViewN/AView Earnings Details
3/21/2013Q412($0.31)($0.29)$7.96 million$9.16 millionViewN/AView Earnings Details
11/13/2012Q312($0.43)($0.35)$8.38 million$7.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for AEterna Zentaris (NASDAQ:AEZS)
Current Year EPS Consensus Estimate: $-1.36 EPS
Next Year EPS Consensus Estimate: $-0.54 EPS

Dividends

Dividend History for AEterna Zentaris (NASDAQ:AEZS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for AEterna Zentaris (NASDAQ:AEZS)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for AEterna Zentaris (NASDAQ:AEZS)
Latest Headlines for AEterna Zentaris (NASDAQ:AEZS)
Source:
DateHeadline
finance.yahoo.com logoAEterna Zentaris Inc. (USA) (AEZS) CEO’s Departure Raises Questions
finance.yahoo.com - July 24 at 1:43 PM
nasdaq.com logoAeterna Zentaris Forms Strategic Review Committee, Appoints Michael Ward As CEO
www.nasdaq.com - July 21 at 2:03 AM
streetinsider.com logoAfter-Hours Stock Movers 07/20: (AEZS) (ATHN) (MSFT) Higher; (MANH) (NCR) (MXIM) Lower (more...)
www.streetinsider.com - July 20 at 9:03 PM
finance.yahoo.com logoAeterna Zentaris Forms Strategic Review Committee and Appoints Michael Ward as CEO
finance.yahoo.com - July 20 at 9:02 PM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE- Sears, Sarepta Qualcomm, A Schulman - Nasdaq
www.nasdaq.com - July 20 at 4:01 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Vertex Pharmaceuticals and Aeterna Zentaris
finance.yahoo.com - July 20 at 4:01 PM
finanznachrichten.de logoGainers & Losers Of July 19: AEZS, VRTX, AGRX, PTI, INO...
www.finanznachrichten.de - July 20 at 2:39 AM
baystreet.ca logoDrug Company More than Doubles in Price on FDA Notification
www.baystreet.ca - July 19 at 4:36 PM
benzinga.com logoMid-Afternoon Market Update: Scripps Rises On Report Of Merger Talks With Discovery; DryShips Shares Slide - Benzinga
www.benzinga.com - July 19 at 4:26 PM
marketwatch.com logoAEterna Zentaris's stock more than doubles on heavy volume after favorable FDA ruling - MarketWatch
www.marketwatch.com - July 19 at 4:26 PM
finance.yahoo.com logoAEterna Zentaris's stock more than doubles on heavy volume after favorable FDA ruling
finance.yahoo.com - July 19 at 4:26 PM
americanbankingnews.com logoAEterna Zentaris Inc. (NASDAQ:AEZS) Price Target Raised to $4.00
www.americanbankingnews.com - July 19 at 1:56 PM
rttnews.com logoFDA Nod For GILD, It's Take 2 For AEZS' Macrilen, VRTX Soars On CF Drug Trials
www.rttnews.com - July 19 at 2:29 AM
streetinsider.com logoAfter-Hours Stock Movers 07/18: (AEZS) (VRTX) (EXPO) Higher; (DRYS) (HDP) (IBM) (CSX) (UAL) Lower (more...) - StreetInsider.com
www.streetinsider.com - July 18 at 9:28 PM
streetinsider.com logoAeterna Zentaris (AEZS) Granted 12/30/17 PDUFA Date for Macrilen NDA Approval - StreetInsider.com
www.streetinsider.com - July 18 at 9:28 PM
finance.yahoo.com logoNDA for Macrilen™ for the Evaluation of Growth Hormone Deficiency in Adults Granted December 30, 2017 PDUFA Date
finance.yahoo.com - July 18 at 9:28 PM
americanbankingnews.com logoAEterna Zentaris Inc. (AEZS) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - July 11 at 6:02 PM
americanbankingnews.com logoBrokerages Expect AEterna Zentaris Inc. (AEZS) to Post ($0.41) EPS
www.americanbankingnews.com - July 10 at 2:30 PM
americanbankingnews.com logoAEterna Zentaris Inc. (AEZS) PT Set at $3.00 by HC Wainwright
www.americanbankingnews.com - July 9 at 6:02 PM
zacks.com logoDo Options Traders Know Something About Aeterna Zentaris (AEZS) Stock We Don't?
www.zacks.com - July 8 at 8:33 PM
nasdaq.com logoDo Options Traders Know Something About Aeterna Zentaris (AEZS) Stock We Don't? - Nasdaq
www.nasdaq.com - July 7 at 5:23 PM
finance.yahoo.com logoDo Options Traders Know Something About Aeterna Zentaris (AEZS) Stock We Don't?
finance.yahoo.com - July 7 at 5:23 PM
americanbankingnews.com logoMaxim Group Analysts Give AEterna Zentaris Inc. (AEZS) a $2.00 Price Target
www.americanbankingnews.com - July 3 at 6:25 PM
streetinsider.com logoAeterna Zentaris (AEZS) Resubmits NDA for Macrilen for Evaluation of AGHD
www.streetinsider.com - June 30 at 8:41 PM
streetinsider.com logoAeterna Zentaris (AEZS) Resubmits NDA for Macrilen for Evaluation ... - StreetInsider.com
www.streetinsider.com - June 30 at 3:39 PM
finance.yahoo.com logoAeterna Zentaris Resubmits NDA for Macrilen™ for the Evaluation of Growth Hormone Deficiency in Adults
finance.yahoo.com - June 30 at 3:38 PM
americanbankingnews.com logoZacks: AEterna Zentaris Inc. (AEZS) Given $2.50 Consensus Target Price by Brokerages
www.americanbankingnews.com - June 23 at 8:40 AM
finance.yahoo.com logoImplied Volatility Surging for Aeterna Zentaris (AEZS) Stock Options
finance.yahoo.com - June 16 at 3:48 PM
businesswire.com logoAeterna Zentaris to Present at 2017 Marcum MicroCap Conference ... - Business Wire (press release)
www.businesswire.com - June 9 at 3:28 PM
finance.yahoo.com logoAeterna Zentaris to Present at 2017 Marcum MicroCap Conference
finance.yahoo.com - June 9 at 3:28 PM
americanbankingnews.com logo AEterna Zentaris Inc. (AEZS) Given Average Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - June 8 at 8:14 AM
finance.yahoo.com logoÆterna Zentaris, Inc. :AEZS-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 4:21 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: AEterna Zentaris and Dynavax Technologies
finance.yahoo.com - May 30 at 11:05 AM
americanbankingnews.com logo AEterna Zentaris Inc. (AEZS) Receives Consensus Recommendation of "" from Analysts
www.americanbankingnews.com - May 24 at 2:34 PM
nasdaq.com logoIs the Options Market Predicting a Spike in Aeterna Zentaris (AEZS) Stock? - Nasdaq
www.nasdaq.com - May 22 at 3:22 PM
finance.yahoo.com logoIs the Options Market Predicting a Spike in Aeterna Zentaris (AEZS) Stock?
finance.yahoo.com - May 22 at 3:22 PM
americanbankingnews.com logoAEterna Zentaris Inc. (AEZS) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - May 12 at 4:40 PM
americanbankingnews.com logoAEterna Zentaris Inc. (AEZS) Price Target Cut to $3.00 by Analysts at HC Wainwright
www.americanbankingnews.com - May 10 at 7:56 AM
finance.yahoo.com logoAeterna Zentaris Announces Election of Directors at 2017 Shareholders' Meeting
finance.yahoo.com - May 9 at 8:23 PM
americanbankingnews.com logoAEterna Zentaris Inc. (AEZS) Announces Earnings Results, Beats Expectations By $0.02 EPS
www.americanbankingnews.com - May 9 at 1:38 PM
finance.yahoo.com logoAeterna Zentaris Reports First Quarter 2017 Financial and Operating Results
finance.yahoo.com - May 8 at 8:21 PM
seekingalpha.com logoAEterna Zentaris: Learning From Mistakes - Seeking Alpha
seekingalpha.com - May 5 at 3:23 PM
americanbankingnews.com logo AEterna Zentaris Inc. (AEZS) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - May 5 at 9:46 AM
americanbankingnews.com logoAEterna Zentaris (AEZS) Given News Sentiment Rating of 0.22
www.americanbankingnews.com - May 3 at 10:15 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: AEterna Zentaris and Exelixis
finance.yahoo.com - May 2 at 3:25 PM
finance.yahoo.com logoAeterna Zentaris to Announce First Quarter 2017 Financial and Operating Results on May 8, 2017
finance.yahoo.com - May 2 at 3:25 PM
bizjournals.com logoIIROC Trading Halt - AEZS
www.bizjournals.com - May 1 at 3:21 PM
streetinsider.com logoAeterna Zentaris (AEZS) Phase 3 Study of Zoptrex Doesn't Achieve Primary Endpoint
www.streetinsider.com - May 1 at 3:21 PM
streetinsider.com logoPre-Open Movers 05/01: (OCN) (XXII) (TWTR) Higher; (FNBC) (AEZS) (ITCI) Lower (more...) - StreetInsider.com
www.streetinsider.com - May 1 at 9:54 AM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-First NBC Bank, Twitter, Tribune Media, Aeterna Zentaris, Neurotrope - Nasdaq
www.nasdaq.com - May 1 at 9:54 AM

Social

Chart

AEterna Zentaris (AEZS) Chart for Monday, July, 24, 2017

This page was last updated on 7/24/2017 by MarketBeat.com Staff